APOE and atherosclerosis: The “lipid metabolic process” comprised 44.2% of up-regulated probe sets of 18-month-old Apoe-/- mice with advanced atherosclerosis-induced heart failure (Figure 1b) and 52.3% of up-regulated probe sets of Apoe-/- mice with rosiglitazone-induced heart failure (Figure 1c).